Tag: Therapeutics

Up to 90% of drug candidates fail during development, largely due to issues with efficacy and safety. Understanding what is the key aspect of drug design—achieving a specific and effective interaction with a biological target—is crucial for improving these statistics and advancing new therapeutic treatments.

In 2022, 23% of adults in the U.S. received some form of mental health treatment, an increase from 19% in 2019 [1.5.1]. When discussing these services, people often ask, 'What is another medical term for therapy?' While 'treatment' is the most common synonym, the answer is nuanced [1.3.4].

According to the CDC, over three out of five drug overdose deaths involve an opioid, illustrating the stark contrast in fatal overdose risk compared to cannabinoids. This critical difference between opioids and cannabinoids is one of many distinctions in their pharmacology, therapeutic applications, and potential for harm.

In pharmacology, a drug's action is defined by how it interacts with cellular receptors, which is why there's no single answer to the question, "What is better, an agonist or an antagonist?". The choice is entirely dependent on the specific medical condition being treated and the therapeutic goal.

With increasing resistance to standard leishmaniasis treatments, scientists are exploring alternative therapies, including the potent antimalarial artemisinin. But what is an artemisinin for leishmaniasis, and how is it being adapted for this debilitating disease?

In November 2024, the U.S. Food and Drug Administration (FDA) approved Attruby (acoramidis) to treat adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This oral medication serves a crucial role in reducing death and hospitalizations related to heart problems caused by this rare and serious condition. If you're asking, **'What is Attruby for?'**, this guide will explain its purpose, function, and other important information for patients.